Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity

Pharmacology and Therapeutics

Volumn 179, Issue , 2017, Pages 84-95

  Bal Price, Anna ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b Bette)   (Canada)

Author keywords

Key event; Key event relationship; Mechanistic understanding; Neurotoxicity; Quantitation; Weight of evidence

Indexed keywords

ENVIRONMENTAL CHEMICAL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ADVERSE OUTCOME; BRAIN DEVELOPMENT; CORPUS STRIATUM; DEGENERATIVE DISEASE; DEVELOPMENTAL TOXICITY; ENVIRONMENTAL EXPOSURE; HUMAN; LEARNING DISORDER; MEMORY DISORDER; MOTOR DYSFUNCTION; NERVE CELL; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; ADVERSE OUTCOME PATHWAY; ANIMAL; CHEMICALLY INDUCED; METABOLISM; POLLUTANT; TOXICITY; TOXICITY AND INTOXICATION;

ADVERSE OUTCOME PATHWAYS; ANIMALS; ENVIRONMENTAL POLLUTANTS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROTOXICITY SYNDROMES; RECEPTORS, N-METHYL-D-ASPARTATE; TOXICITY TESTS;

EID: 85020083235     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.05.006     Document Type: Review

References (132)

1. Adinolfi, M., The development of the human blood-CSF-brain barrier. Developmental Medicine and Child Neurology 27 (1985), 532–537.
2. Anderson, D.W., Pothakos, K., Schneider, J.S., Sex and rearing condition modify the effects of perinatal lead exposure on learning and memory. Neurotoxicology 33 (2012), 985–995.
3. Ankley, G.T., Bennett, R.S., Erickson, R.J., Hoff, D.J., Hornung, M.W., Johnson, R.D., Villeneuve, D.L., Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environmental Toxicology and Chemistry 29 (2010), 730–741.
4. AOP-KB, Adverse Outcome Pathway Knowledge Base (AOP-KB). Jan 28, 2017 http://aopkb.org/.
5. AOP-Wiki, AOP-Wiki. Feb 22, 2017 2017 https://aopwiki.org.
6. Azkona, G., Lopez de Maturana, R., Del Rio, P., Sousa, A., Vazquez, N., Zubiarrain, A., Sanchez-Pernaute, R., LRRK2 expression is deregulated in fibroblasts and neurons from Parkinson patients with mutations in PINK1. Molecular Neurobiology, 2016 (Epub ahead of print).
7. Baghurst, P.A., McMichael, A.J., Wigg, N.R., Vimpani, G.V., Robertson, E.F., Roberts, R.J., Tong, S.L., Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study. The New England Journal of Medicine 327 (1992), 1279–1284.
8. Bai, X., Twaroski, D., Bosnjak, Z.J., Modeling anesthetic developmental neurotoxicity using human stem cells. Seminars in Cardiothoracic and Vascular Anesthesia 17 (2013), 276–287.
9. Bal-Price, A., Coecke, S., Costa, L., Crofton, K.M., Fritsche, E., Goldberg, A., Kreysa, J., Advancing the science of developmental neurotoxicity (DNT): Testing for better safety evaluation. ALTEX 29 (2012), 202–215.
10. Bal-Price, A., Crofton, K.M., Leist, M., Allen, S., Arand, M., Buetler, T., Fritsche, E., International STakeholder NETwork (ISTNET): Creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes. Archives of Toxicology 89 (2015), 269–287.
11. Bal-Price, A., Crofton, K.M., Sachana, M., Shafer, T.J., Behl, M., Forsby, A., Fritsche, E., Putative adverse outcome pathways relevant to neurotoxicity. Critical Reviews in Toxicology 45 (2015), 83–91.
12. Bal-Price, A., Lein, P.J., Keil, K.P., Sethi, S., Shafer, T., Barenys, M., Meek, M.E., Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity. Neurotoxicology 59 (2017), 240–255.
13. Baumann, J., Barenys, M., Gassmann, K., Fritsche, E., Comparative human and rat “neurosphere assay” for developmental neurotoxicity testing. Current Protocols in Toxicology 59 (2014), 11–24 (12 21).
14. Becker, R.A., Ankley, G.T., Edwards, S.W., Kennedy, S.W., Linkov, I., Meek, B., Barton-Maclaren, T.S., Increasing scientific confidence in adverse outcome pathways: Application of tailored Bradford-Hill considerations for evaluating weight of evidence. Regulatory Toxicology and Pharmacology 72 (2015), 514–537.
15. Bellinger, D.C., Lead. Pediatrics 113 (2004), 1016–1022.
16. Beltrao-Braga, P.C., Muotri, A.R., Modeling autism spectrum disorders with human neurons. Brain Research 1656 (2017), 49–54.
17. Bernardi, P., Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiological Reviews 79 (1999), 1127–1155.
18. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seitelberger, F., Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences 20 (1973), 415–455.
19. Betarbet, R., Sherer, T.B., Greenamyre, J.T., Ubiquitin-proteasome system and Parkinson's diseases. Experimental Neurology 191:Suppl. 1 (2005), S17–S27.
20. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., Greenamyre, J.T., Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience 3 (2000), 1301–1306.
21. Bove, J., Perier, C., Neurotoxin-based models of Parkinson's disease. Neuroscience 211 (2012), 51–76.
22. Burns, R.S., LeWitt, P.A., Ebert, M.H., Pakkenberg, H., Kopin, I.J., The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The New England Journal of Medicine 312 (1985), 1418–1421.
23. Calne, D.B., Sandler, M., L-Dopa and parkinsonism. Nature 226 (1970), 21–24.
24. Canfield, R.L., Henderson, C.R. Jr., Cory-Slechta, D.A., Cox, C., Jusko, T.A., Lanphear, B.P., Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. The New England Journal of Medicine 348 (2003), 1517–1526.
25. Chen, Y., McMillan-Ward, E., Kong, J., Israels, S.J., Gibson, S.B., Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. Journal of Cell Science 120 (2007), 4155–4166.
26. Cherra, S.J. III, Kulich, S.M., Uechi, G., Balasubramani, M., Mountzouris, J., Day, B.W., Chu, C.T., Regulation of the autophagy protein LC3 by phosphorylation. The Journal of Cell Biology 190 (2010), 533–539.
27. Chtitaa, S., Larifb, M., Ghamalia, M., Bouachrinec, M., Lakhlifia, T., DFT-based QSAR Studies of MK801 derivatives for non competitive antagonists of NMDA using electronic and topological descriptors. Journal of Taibah University for Science 9 (2015), 143–154.
28. Cleeter, M.W., Cooper, J.M., Schapira, A.H., Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement. Journal of Neurochemistry 58 (1992), 786–789.
29. Costa, A.P., Steffgen, G., Samson, A.C., Expressive incoherence and alexithymia in autism spectrum disorder. Journal of Autism and Developmental Disorders, 2017 Mar 6, 10.1007/s10803-017-3073-9 (Epub ahead of print).
30. Domingues, A.F., Arduino, D.M., Esteves, A.R., Swerdlow, R.H., Oliveira, C.R., Cardoso, S.M., Mitochondria and ubiquitin-proteasomal system interplay: Relevance to Parkinson's disease. Free Radical Biology & Medicine 45 (2008), 820–825.
31. EC, Executive summary. 7th amendment to the EU cosmetics directive. Feb 20, 2017 http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/antest/(2)_executive_summary_en.pdf, 2017.
32. EC, REACH Implementation. http://ec.europa.eu/environment/chemicals/reach/implementation_en.htm, 2017.
33. Edwards, S.W., Tan, Y.M., Villeneuve, D.L., Meek, M.E., McQueen, C.A., Adverse outcome pathways-organizing toxicological information to improve decision making. The Journal of Pharmacology and Experimental Therapeutics 356 (2016), 170–181.
34. EPA, Assessing and managing chemicals under TSCA. Jan 27, 2017 https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/frank-r-lautenberg-chemical-safety-21st-century-act-5#risk, 2016.
35. Esteves, A.R., Arduino, D.M., Silva, D.F., Oliveira, C.R., Cardoso, S.M., Mitochondrial dysfunction: The road to alpha-synuclein oligomerization in PD. Parkinson's Disease, 2011, 2011, 693761.
36. Finkelstein, Y., Markowitz, M.E., Rosen, J.F., Low-level lead-induced neurotoxicity in children: An update on central nervous system effects. Brain Research. Brain Research Reviews 27 (1998), 168–176.
37. Fornai, F., Schluter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Sudhof, T.C., Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America 102 (2005), 3413–3418.
38. Friend, S.H., Schadt, E.E., Translational genomics. Clues from the resilient. Science 344 (2014), 970–972.
39. Fritsche, E., Crofton, K.M., Hernandez, A.F., Hougaard Bennekou, S., Leist, M., Bal-Price, A., Gourmelon, A., OECD/EFSA Workshop on Developmental Neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes. ALTEX 34:2 (2017), 311–315.
40. Fujita, K.A., Ostaszewski, M., Matsuoka, Y., Ghosh, S., Glaab, E., Trefois, C., Balling, R., Integrating pathways of Parkinson's disease in a molecular interaction map. Molecular Neurobiology 49 (2014), 88–102.
41. Grandjean, P., Landrigan, P.J., Neurobehavioural effects of developmental toxicity. Lancet Neurology 13 (2014), 330–338.
42. Granger, A.J., Gray, J.A., Lu, W., Nicoll, R.A., Genetic analysis of neuronal ionotropic glutamate receptor subunits. The Journal of Physiology 589 (2011), 4095–4101.
43. Greenamyre, J.T., Sherer, T.B., Betarbet, R., Panov, A.V., Complex I and Parkinson's disease. IUBMB Life 52 (2001), 135–141.
44. Haberny, K.A., Paule, M.G., Scallet, A.C., Sistare, F.D., Lester, D.S., Hanig, J.P., Slikker, W. Jr., Ontogeny of the N-methyl-D-aspartate (NMDA) receptor system and susceptibility to neurotoxicity. Toxicological Sciences 68 (2002), 9–17.
45. Harrill, J.A., Chen, H., Streifel, K.M., Yang, D., Mundy, W.R., Lein, P.J., Ontogeny of biochemical, morphological and functional parameters of synaptogenesis in primary cultures of rat hippocampal and cortical neurons. Molecular Brain, 8, 2015, 10.
46. Hofmann-Apitius, M., Alarcon-Riquelme, M.E., Chamberlain, C., McHale, D., Towards the taxonomy of human disease. Nature Reviews. Drug Discovery 14 (2015), 75–76.
47. Hogberg, H.T., Kinsner-Ovaskainen, A., Coecke, S., Hartung, T., Bal-Price, A.K., mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach. Toxicological Sciences 113 (2010), 95–115.
48. Hogberg, H.T., Kinsner-Ovaskainen, A., Hartung, T., Coecke, S., Bal-Price, A.K., Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells (CGCs) exposed to pesticides. Toxicology and Applied Pharmacology 235 (2009), 268–286.
49. Hoglinger, G.U., Carrard, G., Michel, P.P., Medja, F., Lombes, A., Ruberg, M., Hirsch, E.C., Dysfunction of mitochondrial complex I and the proteasome: Interactions between two biochemical deficits in a cellular model of Parkinson's disease. Journal of Neurochemistry 86 (2003), 1297–1307.
50. Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Perani, D., In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism & Related Disorders 19 (2013), 47–52.
51. Ikawa, M., Okazawa, H., Kudo, T., Kuriyama, M., Fujibayashi, Y., Yoneda, M., Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nuclear Medicine and Biology 38 (2011), 945–951.
52. Iyappan, A., Gundel, M., Shahid, M., Wang, J., Li, H., Mevissen, H.T., Hofmann-Apitius, M., Towards a pathway inventory of the human brain for modeling disease mechanisms underlying neurodegeneration. Journal of Alzheimer's Disease 52 (2016), 1343–1360.
53. Kalkbrenner, A.E., Schmidt, R.J., Penlesky, A.C., Environmental chemical exposures and autism spectrum disorders: A review of the epidemiological evidence. Current Problems in Pediatric and Adolescent Health Care 44 (2014), 277–318.
54. Kola, I., Bell, J., A call to reform the taxonomy of human disease. Nature Reviews Drug Discovery 10:9 (2011), 641–642.
55. Koller, W.C., When does Parkinson's disease begin?. Neurology 42 (1992), 27–31 (discussion 41-28).
56. Krewski, D., Acosta, D. Jr., Andersen, M., Anderson, H., Bailar, J.C. III, Boekelheide, K., Zeise, L., Toxicity testing in the 21st century: A vision and a strategy. Journal of Toxicology and Environmental Health. Part B, Critical Reviews 13 (2010), 51–138.
57. Krug, A.K., Balmer, N.V., Matt, F., Schonenberger, F., Merhof, D., Leist, M., Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Archives of Toxicology 87 (2013), 2215–2231.
58. Langley, G.R., Adcock, I.M., Busquet, F., Crofton, K.M., Csernok, E., Giese, C., Woszczek, G., Towards a 21st-century roadmap for biomedical research and drug discovery: Consensus report and recommendations. Drug Discovery Today 22 (2017), 327–339.
59. Langston, J.W., Langston, E.B., Irwin, I., MPTP-induced parkinsonism in human and non-human primates—clinical and experimental aspects. Acta Neurologica Scandinavica. Supplementum 100 (1984), 49–54.
60. Lanphear, B.P., Hornung, R., Khoury, J., Yolton, K., Baghurst, P., Bellinger, D.C., Roberts, R., Low-level environmental lead exposure and children's intellectual function: An international pooled analysis. Environmental Health Perspectives 113 (2005), 894–899.
61. Lee, D.H., Kim, C.S., Lee, Y.J., Astaxanthin protects against MPTP/MPP +-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food and Chemical Toxicology 49 (2011), 271–280.
62. Lee, H.J., Shin, S.Y., Choi, C., Lee, Y.H., Lee, S.J., Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. The Journal of Biological Chemistry 277 (2002), 5411–5417.
63. Leenders, K.L., Palmer, A.J., Quinn, N., Clark, J.C., Firnau, G., Garnett, E.S., Marsden, C.D., Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. Journal of Neurology, Neurosurgery, and Psychiatry 49 (1986), 853–860.
64. Lin, M.T., Beal, M.F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006), 787–795.
65. Lotharius, J., Brundin, P., Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nature Reviews. Neuroscience 3 (2002), 932–942.
66. Lyall, K., Croen, L., Daniels, J., Fallin, M.D., Ladd-Acosta, C., Lee, B.K., Newschaffer, C., The changing epidemiology of autism spectrum disorders. Annual Review of Public Health 38 (2017, Mar 20), 81–102.
67. Marchetto, M.C., Carromeu, C., Acab, A., Yu, D., Yeo, G.W., Mu, Y., Muotri, A.R., A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143 (2010), 527–539.
68. McDonald, M.E., Paul, J.F., Timing of increased autistic disorder cumulative incidence. Environmental Science & Technology 44 (2010), 2112–2118.
69. McNaught, K.S., Olanow, C.W., Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease. Annals of Neurology 53:Suppl. 3 (2003), S73–S84 (discussion S84-76).
70. McNaught, K.S., Olanow, C.W., Halliwell, B., Isacson, O., Jenner, P., Failure of the ubiquitin-proteasome system in Parkinson's disease. Nature Reviews. Neuroscience 2 (2001), 589–594.
71. Meek, M.E., Armstrong, V.C., The assessment and management of industrial chemicals in Canada. Leeuwen, C.J., van Vermeire, T.G., (eds.) Risk assessment of chemicals: An introduction, 2nd ed., 2007, Kluwer Academic Publishers, Dordrecht, the Netherlands, 591–621.
72. Meek, M.E., Boobis, A., Cote, I., Dellarco, V., Fotakis, G., Munn, S., Vickers, C., New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. Journal of Applied Toxicology 34 (2014), 1–18.
73. Meek, M.E., Palermo, C.M., Bachman, A.N., North, C.M., Jeffrey Lewis, R., Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. Journal of Applied Toxicology 34 (2014), 595–606.
74. Mena, M.A., Garcia de Yebenes, J., Glial cells as players in parkinsonism: The “good,” the “bad,” and the “mysterious” glia. The Neuroscientist 14 (2008), 544–560.
75. Moreira, E.G., Vassilieff, I., Vassilieff, V.S., Developmental lead exposure: Behavioral alterations in the short and long term. Neurotoxicology and Teratology 23 (2001), 489–495.
76. Mundy, W.R., Robinette, B., Radio, N.M., Freudenrich, T.M., Protein biomarkers associated with growth and synaptogenesis in a cell culture model of neuronal development. Toxicology 249 (2008), 220–229.
77. Murphy, K.J., Regan, C.M., Low-level lead exposure in the early postnatal period results in persisting neuroplastic deficits associated with memory consolidation. Journal of Neurochemistry 72 (1999), 2099–2104.
78. National Research Council (NRC), Toxicity Testing in the Twenty-First Century: A Vision and a Strategy. 2007, National Academy of Sciences, Washington, DC.
79. Neal, A.P., Stansfield, K.H., Worley, P.F., Thompson, R.E., Guilarte, T.R., Lead exposure during synaptogenesis alters vesicular proteins and impairs vesicular release: Potential role of NMDA receptor-dependent BDNF signaling. Toxicological Sciences 116 (2010), 249–263.
80. Neal, A.P., Worley, P.F., Guilarte, T.R., Lead exposure during synaptogenesis alters NMDA receptor targeting via NMDA receptor inhibition. Neurotoxicology 32 (2011), 281–289.
81. Needleman, H.L., Gatsonis, C.A., Low-level lead exposure and the IQ of children. A meta-analysis of modern studies. JAMA 263 (1990), 673–678.
82. NICNAS, Australian inventory multi-tiered assessment and prioritisation. Jan 28, 2017 https://www.nicnas.gov.au/chemical-information/imap-assessments, 2017.
83. Ntzani, E.E., Chondrogiorgi, M., Ntritsos, G., Evangelou, E., Tzoulaki, E.E., Literature review on epidemiological studies linking exposure to pesticides and health effects. http://onlinelibrary.wiley.com/doi/10.2903/sp.efsa.2013.EN-497/pdf, 2013.
84. OECD, Guidance document on developing and assessing adverse outcome pathways. No. 184 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono%282013%296&doclanguage=en, 2013.
85. OECD, OECD series on adverse outcome pathways. Feb 24, 2017 http://www.oecd-ilibrary.org/environment/oecd-series-on-adverse-outcome-pathways_2415170x, 2016.
86. OECD, Users’ handbook supplement to the guidance document for developing and assessing adverse outcome pathways. 2016, 10.1787/5jlv1m9d1g32-en.
87. Ogura, H., Aigner, T.G., MK-801 impairs recognition memory in rhesus monkeys: Comparison with cholinergic drugs. The Journal of Pharmacology and Experimental Therapeutics 266 (1993), 60–64.
88. Ojha, S., Javed, H., Azimullah, S., Abul Khair, S.B., Haque, M.E., Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease. Drug Design, Development and Therapy 9 (2015), 5499–5510.
89. Pamies, D., Barreras, P., Block, K., Makri, G., Kumar, A., Wiersma, D., Hogberg, H.T., A human brain microphysiological system derived from induced pluripotent stem cells to study neurological diseases and toxicity. ALTEX, 2016, 10.14573/altex.1609122 (Epub ahead of print).
90. Parker, W.D. Jr., Swerdlow, R.H., Mitochondrial dysfunction in idiopathic Parkinson disease. American Journal of Human Genetics 62 (1998), 758–762.
91. Pistollato, F., Cavanaugh, S.E., Chandrasekera, P.C., A human-based integrated framework for Alzheimer's disease research. Journal of Alzheimer's Disease 47 (2015), 857–868.
92. Pistollato, F., Ohayon, E.L., Lam, A., Langley, G.R., Novak, T.J., Pamies, D., Chandrasekera, P.C., Alzheimer disease research in the 21st century: Past and current failures, new perspectives and funding priorities. Oncotarget 7 (2016), 38999–39016.
93. Plenge, R.M., Scolnick, E.M., Altshuler, D., Validating therapeutic targets through human genetics. Nature Reviews. Drug Discovery 12 (2013), 581–594.
94. Reisinger, K., Hoffmann, S., Alepee, N., Ashikaga, T., Barroso, J., Elcombe, C., Maxwell, G., Systematic evaluation of non-animal test methods for skin sensitisation safety assessment. Toxicology In Vitro 29 (2015), 259–270.
95. Rezvani, A.H., Involvement of the NMDA system in learning and memory. Levin, E.D., Buccafusco, J.J., (eds.) Animal models of cognitive impairment, 2006, Taylor & Francis Group, LLC, Boca Raton FL.
96. Rice, D., Barone, S. Jr., Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. Environmental Health Perspectives 108:Suppl. 3 (2000), 511–533.
97. Rodier, Developing brain as a target of toxicity. Environmental Health Perspectives 103 (1995, Sep), 73–76.
98. Russo, F.B., Cugola, F.R., Fernandes, I.R., Pignatari, G.C., Beltrao-Braga, P.C., Induced pluripotent stem cells for modeling neurological disorders. World Journal of Transplantation 5 (2015), 209–221.
99. Saha, A.R., Hill, J., Utton, M.A., Asuni, A.A., Ackerley, S., Grierson, A.J., Hanger, D.P., Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. Journal of Cell Science 117 (2004), 1017–1024.
100. Sanders, L.H., Greenamyre, J.T., Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radical Biology & Medicine 62 (2013), 111–120.
101. Sanders, T., Liu, Y., Buchner, V., Tchounwou, P.B., Neurotoxic effects and biomarkers of lead exposure: A review. Reviews on Environmental Health 24 (2009), 15–45.
102. Schadt, E.E., Bjorkegren, J.L., NEW: Network-enabled wisdom in biology, medicine, and health care. Science Translational Medicine, 4, 2012, 115rv111.
103. Schapira, A.H., Etiology of Parkinson's disease. Neurology 66 (2006), S10–S23.
104. Schwartz, M.P., Hou, Z., Propson, N.E., Zhang, J., Engstrom, C.J., Santos Costa, V., Thomson, J.A., Human pluripotent stem cell-derived neural constructs for predicting neural toxicity. Proceedings of the National Academy of Sciences of the United States of America 112 (2015), 12516–12521.
105. Segura-Aguilar, J., Kostrzewa, R.M., Neurotoxin mechanisms and processes relevant to Parkinson's disease: An update. Neurotoxicity Research 27 (2015), 328–354.
106. Sherer, T.B., Betarbet, R., Stout, A.K., Lund, S., Baptista, M., Panov, A.V., Greenamyre, J.T., An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. The Journal of Neuroscience 22 (2002), 7006–7015.
107. Sherer, T.B., Betarbet, R., Testa, C.M., Seo, B.B., Richardson, J.R., Kim, J.H., Greenamyre, J.T., Mechanism of toxicity in rotenone models of Parkinson's disease. The Journal of Neuroscience 23 (2003), 10756–10764.
108. Siegel, G.J., Agranoff, B.W., Albers, R.W., Fisher, S.K., Uhler, M.D., MPTP-induced parkinsonian syndrome. Basic neurochemistry: Molecular, cellular and medical aspects, 6th ed., 1999, Lippincott Williams and Wilkins, 934–940.
109. Snow, B.J., Vingerhoets, F.J., Langston, J.W., Tetrud, J.W., Sossi, V., Calne, D.B., Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. Journal of Neurology, Neurosurgery, and Psychiatry 68 (2000), 313–316.
110. Song, L., Cortopassi, G., Mitochondrial complex I defects increase ubiquitin in substantia nigra. Brain Research 1594 (2015), 82–91.
111. Sonich-Mullin, C., Fielder, R., Wiltse, J., Baetcke, K., Dempsey, J., Fenner-Crisp, P., Younes, M., IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regulatory Toxicology and Pharmacology 34 (2001), 146–152.
112. Tsukamoto, T., Animal disease models for drug screening: the elephant in the room?. Drug Discovery Today 21 (2016), 529–530.
113. van der Staay, F.J., Rutten, K., Erb, C., Blokland, A., Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behavioural Brain Research 220 (2011), 215–229.
114. von Stackelberg, K., Guzy, E., Chu, T., Claus Henn, B., Exposure to mixtures of metals and neurodevelopmental outcomes: A multidisciplinary review using an adverse outcome pathway framework. Risk Analysis 35 (2015), 971–1016.
115. Stansfield, K.H., Pilsner, J.R., Lu, Q., Wright, R.O., Guilarte, T.R., Dysregulation of BDNF-TrkB signaling in developing hippocampal neurons by Pb(2 +): Implications for an environmental basis of neurodevelopmental disorders. Toxicological Sciences 127 (2012), 277–295.
116. Sulzer, D., Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends in Neurosciences 30 (2007), 244–250.
117. Surkan, P.J., Zhang, A., Trachtenberg, F., Daniel, D.B., McKinlay, S., Bellinger, D.C., Neuropsychological function in children with blood lead levels < 10 microg/dL. Neurotoxicology 28 (2007), 1170–1177.
118. Tanner, C.M., Kamel, F., Ross, G.W., Hoppin, J.A., Goldman, S.M., Korell, M., Langston, J.W., Rotenone, paraquat, and Parkinson's disease. Environmental Health Perspectives 119 (2011), 866–872.
119. Thomas, B., Banerjee, R., Starkova, N.N., Zhang, S.F., Calingasan, N.Y., Yang, L., Starkov, A., Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease. Antioxidants & Redox Signaling 16 (2012), 855–868.
120. Tollefsen, K.E., Scholz, S., Cronin, M.T., Edwards, S.W., de Knecht, J., Crofton, K., Patlewicz, G., Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA). Regulatory Toxicology and Pharmacology 70 (2014), 629–640.
121. Toscano, C.D., Guilarte, T.R., Lead neurotoxicity: From exposure to molecular effects. Brain Research. Brain Research Reviews 49 (2005), 529–554.
122. Verkhratsky, A., Parpura, V., Pekna, M., Pekny, M., Sofroniew, M., Glia in the pathogenesis of neurodegenerative diseases. Biochemical Society Transactions 42 (2014), 1291–1301.
123. Villeneuve, D.L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T.H., LaLone, C.A., Whelan, M., Adverse outcome pathway (AOP) development I: Strategies and principles. Toxicological Sciences 142 (2014), 312–320.
124. Villeneuve, D.L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T.H., LaLone, C.A., Whelan, M., Adverse outcome pathway development II: Best practices. Toxicological Sciences 142 (2014), 321–330.
125. Wittwehr, C., Aladjov, H., Ankley, G., Byrne, H.J., de Knecht, J., Heinzle, E., Whelan, M., How adverse outcome pathways can aid the development and use of computational prediction models for regulatory toxicology. Toxicological Sciences 155 (2017), 326–336.
126. Wong, E.H., Kemp, J.A., Priestley, T., Knight, A.R., Woodruff, G.N., Iversen, L.L., The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proceedings of the National Academy of Sciences of the United States of America 83 (1986), 7104–7108.
127. Worth, A.P., Patlewicz, G., Integrated approaches to testing and assessment. Advances in Experimental Medicine and Biology 856 (2016), 317–342.
128. Yahata, N., Asai, M., Kitaoka, S., Takahashi, K., Asaka, I., Hioki, H., Inoue, H., Anti-Abeta drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One, 6, 2011, e25788.
129. Yang, D., Kania-Korwel, I., Ghogha, A., Chen, H., Stamou, M., Bose, D.D., Lein, P.J., PCB 136 atropselectively alters morphometric and functional parameters of neuronal connectivity in cultured rat hippocampal neurons via ryanodine receptor-dependent mechanisms. Toxicological Sciences 138 (2014), 379–392.
130. Zagoura, D., Canovas-Jorda, D., Pistollato, F., Bremer-Hoffmann, S., Bal-Price, A., Evaluation of the rotenone-induced activation of the Nrf2 pathway in a neuronal model derived from human induced pluripotent stem cells. Neurochemistry International 106 (2017), 62–73.
131. Zaltieri, M., Longhena, F., Pizzi, M., Missale, C., Spano, P., Bellucci, A., Mitochondrial dysfunction and alpha-synuclein synaptic pathology in Parkinson's disease: Who's on first?. Parkinson's Disease, 2015, 2015, 108029.
132. Zhu, J., Chu, C.T., Mitochondrial dysfunction in Parkinson's disease. Journal of Alzheimer's Disease 20:Suppl. 2 (2010), S325–S334.